Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Allergan | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Allergan

BOTOX revenues drive growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Allergan
 
3Q Revenues: $3.6 billion (+4%)

3Q Earnings: $15.2 billion (earnings were $5.2 billion 3Q15)*

YTD Revenues: $10.7 billion (+18%)

YTD Earnings: $15.0 billion (earnings were $4.5 billion YTD15)*

Comments: Growth in the quarter was driven key brands and new product launches, offset by the loss of ASACOL HD exclusivity, lower revenues for NAMENDA XRand IR, a decline in non-promoted Established Brands revenues and unfavorable foreign exchange. ASACOL sales were down to $72.2 million in the quarter. NAMENDA sales were $146.9 million, down 32%. RESTASIS revenues in the quarter were $356.4 million, up 14%. BOTOX Cosmetic revenues were $174.5 million, up 10% and BOTOX Therapeutic revenues were $305.5 million, up 17% driven by strong demand across overactive bladder, chronic migraine and adult spasticity indications.
 
*Earnings reflect income from discontinued operations, including the divestiture of the company’s Global Generics business to Teva on August 2, 2016.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters